Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxycodone
Drug ID BADD_D01645
Description Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917.[A178696] It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950.[L6460]
Indications and Usage Oxycodone is indicated for the treatment of moderate to severe pain.[Label] There is also an extended release formulation indicated for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label]
Marketing Status approved; illicit; investigational
ATC Code N02AA05
DrugBank ID DB00497
KEGG ID D05312
MeSH ID D010098
PubChem ID 5284603
TTD Drug ID D07WPQ
NDC Product Code 71335-0981; 67651-0304; 67651-0305; 67651-0306; 24510-140; 71335-1080; 0904-6966; 24510-130; 65162-048; 67877-625; 71335-0677; 65162-050; 0904-7180; 65162-047; 72162-1812; 67877-623; 67651-0302; 65162-049; 67651-0303; 65162-051; 24510-110; 24510-115; 71335-1023; 24510-120; 72162-1811
UNII CD35PMG570
Synonyms Oxycodone | Dihydrone | Oxycone | Dihydrohydroxycodeinone | Oxycodeinon | Eucodal | Theocodin | Oxycodone Hydrochloride | Oxycontin | Pancodine | Dinarkon | Oxiconum
Chemical Information
Molecular Formula C18H21NO4
CAS Registry Number 76-42-6
SMILES CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hepatic cancer recurrent09.04.02.011; 16.07.02.0060.000021%-
Poor feeding infant14.03.02.022; 18.04.06.0060.000021%-
Toxic leukoencephalopathy12.03.01.059; 17.13.02.0120.000259%-
Disorganised speech17.02.08.017; 19.19.02.0050.000166%-
Substance dependence19.07.06.0190.000031%-
Mental fatigue17.03.03.006; 19.21.02.0120.000021%-
Infantile back arching15.03.05.018; 18.04.01.0170.000021%-
Allergic reaction to excipient10.01.01.035---
Attention deficit hyperactivity disorder19.21.04.0040.000145%-
Behaviour disorder19.01.01.0050.000207%-
Congestive hepatopathy02.05.04.018; 09.01.06.0270.000031%-
Drug effect less than expected08.06.01.036---
Drug use disorder19.07.06.0120.000207%-
Foreign body embolism12.02.05.054; 24.01.01.0400.000021%-
Foreign body reaction08.01.05.016; 23.03.15.0120.000041%-
Inadequate analgesia08.06.01.040; 12.02.20.0060.002204%-
Myocardial injury02.04.02.0460.000041%-
Narcotic bowel syndrome07.02.05.0060.000041%-
Near death experience17.02.04.023; 19.10.05.0070.000062%-
Paranoid personality disorder19.05.05.0010.000021%-
Paroxysmal sympathetic hyperactivity12.01.10.018; 17.05.01.0300.000052%-
Precancerous condition08.03.04.010---
Reaction to excipient10.01.01.0420.000116%-
Resorption bone increased14.04.04.020; 15.02.03.0210.000021%-
Self-consciousness19.05.01.025---
Substance use disorder19.07.06.0200.000062%-
Therapeutic product effect increased08.06.01.0530.000203%-
Therapeutic product effect variable08.06.01.055---
The 16th Page    First    Pre   16    Total 16 Pages